UCB SA (UCB) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

141.42 k

Shareholding (Dec 2023)

FII

0.05%

Held by 2 FIIs

DII

99.95%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Operating profit has grown by an annual rate 1.45% of over the last 5 years

With ROE of 14.86%, it has a Very Expensive valuation with a 4.99 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

EUR 46,642 Million ()

P/E

34.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.11

Return on Equity

14.86%

Price to Book

4.82

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2012)

Net Profit:

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

18.76%

6 Months

50.93%

1 Year

27.34%

2 Years

235.62%

3 Years

224.01%

4 Years

148.45%

5 Years

171.81%

UCB SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.67%

EBIT Growth (5y)

1.45%

EBIT to Interest (avg)

6.54

Debt to EBITDA (avg)

0.98

Net Debt to Equity (avg)

0.11

Sales to Capital Employed (avg)

0.50

Tax Ratio

8.43%

Dividend Payout Ratio

17.36%

Pledged Shares

Institutional Holding

0.06%

ROCE (avg)

9.31%

ROE (avg)

9.12%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.99

EV to EBIT

40.48

EV to EBITDA

26.61

EV to Capital Employed

4.60

EV to Sales

7.22

PEG Ratio

0.07

Dividend Yield

ROCE (Latest)

11.36%

ROE (Latest)

14.86%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.05%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'12 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2012 is 0.00% vs 0.00% in Dec 2011",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2012 is 0.00% vs 0.00% in Dec 2011",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'12",
        "Dec'11",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.14% vs -4.80% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 210.50% vs -18.33% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,152.00",
          "val2": "5,252.00",
          "chgp": "17.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,001.00",
          "val2": "970.00",
          "chgp": "3.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "159.00",
          "val2": "144.00",
          "chgp": "10.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-129.00",
          "val2": "-1.00",
          "chgp": "-12,800.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,065.00",
          "val2": "343.00",
          "chgp": "210.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "58.50%",
          "val2": "53.10%",
          "chgp": "0.54%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'12 - YoY

Dec'12

Dec'11

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

0.00

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

0.00

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2012 is 0.00% vs 0.00% in Dec 2011

Consolidated Net Profit

YoY Growth in quarter ended Dec 2012 is 0.00% vs 0.00% in Dec 2011

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

6,152.00

5,252.00

17.14%

Operating Profit (PBDIT) excl Other Income

1,001.00

970.00

3.20%

Interest

159.00

144.00

10.42%

Exceptional Items

-129.00

-1.00

-12,800.00%

Consolidate Net Profit

1,065.00

343.00

210.50%

Operating Profit Margin (Excl OI)

58.50%

53.10%

0.54%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 17.14% vs -4.80% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 210.50% vs -18.33% in Dec 2023

All Annual Results

Company CV

About UCB SA

UCB SA

Pharmaceuticals & Biotechnology

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Company Coordinates

Company Details

Allee de la Recherche, 60 , ANDERLECHT None : 1070

Tel: 32 2 559999932 5 5599414

https://www.ucb.com

Registrar Details